II. Indications
- Primary Immunization series
- Travel to endemic area
- Asia
- Africa
III. Pathophysiology
- Reasoning in switch from oral live (OPV) to injected inactivated (EIPV)
- Rare risk of Poliomyelitis with oral Polio Vaccine (OPV)
- See Oral Polio Vaccine complications below
- All Inactivated Polio Vaccine (EIPV) would result in no cases of polio
- But decreased mucosal (GI, mucus membrane) Immunity
- Chance for exposure from cases from Endemic areas
- China
- India
IV. Contraindications to OPV
- Immunodeficiency disorders
- Household contacts of immunodeficient person
- Pregnancy
- Hypersensitivity to Vaccine
- Anaphylactic reaction to neomycin or Streptomycin
V. Dose
- Adults: EIPV 0.5 ml SC
VI. Dosing: Primary Series Schedule
- Dose 1: Age 2 months
- Dose 2: Age 4 months
- Dose 3: Age 6 to 18 months
- Dose 4: Age 4 to 6 years
VII. Precaution
- EIPV is Safe in HIV and Pregnancy
- Avoid OPV in HIV and Pregnancy
VIII. Complications: Oral Polio Vaccine (OPV)
- Cases per year Poliomyelitis associated with OPV: 8
- One case per 2 million doses
- EIPV results in no cases of Poliomyelitis
IX. Resources
- CDC Immunization Schedules (last accessed 10/28/2020)